Jefferies Lilfts Price Target on BioMarin (BMRN)
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $33.64 +1.11%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Jefferies raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $33 to $35 while maintaining a Buy rating.
The firm comments, "Reported ~3-5% higher 2Q11 revenue of $110.6M (vs. our/cons estimates of $107.0M/$105.3M) on higher Naglazyme sales; /GALNS Ph2 extension data for additional 24 weeks shows sustained benefits for ~2 years, with Ph3 data release on track for 2H12. On increased probability for GALNS, we are raising our PT to $35 from $33."
For more ratings news on BioMarin Pharmaceutical Inc. click here and for the rating history of BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $29.29 yesterday.
The firm comments, "Reported ~3-5% higher 2Q11 revenue of $110.6M (vs. our/cons estimates of $107.0M/$105.3M) on higher Naglazyme sales; /GALNS Ph2 extension data for additional 24 weeks shows sustained benefits for ~2 years, with Ph3 data release on track for 2H12. On increased probability for GALNS, we are raising our PT to $35 from $33."
For more ratings news on BioMarin Pharmaceutical Inc. click here and for the rating history of BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $29.29 yesterday.
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
